GeoVax Labs Inc.

06/17/2026 | Press release | Distributed by Public on 06/17/2026 14:33

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
The Company held its annual meeting of stockholders on June 17, 2026. The Company received proxies totaling 1,288,684 of its 2,892,570 issued and outstanding shares of common stock as of the record date of April 20, 2026. The stockholders voted on the following proposals and the results of the voting are presented below.
Election of Directors
Our stockholders voted to elect the slate of directors consisting of seven members to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified. There were a total of 810,066 broker non-votes on this item.
Nominee
For
Withheld
Randal D. Chase
420,305
58,313
David A. Dodd
418,963
59,655
Dean G. Kollintzas
420,198
58,420
Nicole Lemerond
417,920
61,426
Robert T. McNally
419,481
59,137
Jayne Morgan
420,422
58,196
John N. Spencer, Jr.
420,434
58,184
Approval of the February 2026 Warrant Exercise Proposal
Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 865,804 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the private placement offering which occurred on February 17, 2026. There were a total of 810,066 broker non-votes on this item.
For
Against
Abstain
395,198
65,103
18,317
Approval of the March 2026 Warrant Exercise Proposal
Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,269,316 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on March 31, 2026. There were a total of 810,066 broker non-votes on this item.
For
Against
Abstain
395,365
66,838
16,415
Approval of the May 2026 Warrant Exercise Proposal
Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,702,986 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on May 7, 2026. There were a total of 810,066 broker non-votes on this item.
For
Against
Abstain
375,831
35,336
67,451
Ratification of Independent Auditor
Our stockholders approved the ratification of Wipfli LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. There were no broker non-votes on this item.
For
Against
Abstain
1,185,525
37,409
65,750
2
Advisory Vote on the Compensation of our Named Executive Officers
Our stockholders approved, on an advisory basis, the compensation of our Named Executive Officers (as defined in the Proxy Statement). There were a total of 810,066 broker non-votes on this item.
For
Against
Abstain
385,843
65,826
26,949
Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers
Our stockholders approved, on an advisory basis, the frequency of future advisory votes on the compensation of our Named Executive Officers (as defined in the Proxy Statement). The determination was to hold such advisory votes on a three-year cycle.
1 Year
2 Years
3 Years
Abstain
339,064
24,463
97,058
18,033
3
GeoVax Labs Inc. published this content on June 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 17, 2026 at 20:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]